There is one Phase I trial registered as NCT02637284 in 2015, intended to enrol forty-two participants, which was subsequently cancelled with no published results [7]
From an integrative and preventive standpoint: GGT below 2025 U/L is often considered optimal Risk begins to rise even within the reference range Numerous studies demonstrate increased disease risk at GGT levels still labeled normal by standard labs
Both BmTrxR and PfTrxR are validated drug targets against lymphatic filariasis and malaria, respectively 56,57
Mol Endocrinol (2003) 17(11):222839.10.1210/me.2003-0011 142 PileckaIPatrignaniCPesciniRCurchodMLPerrinDXueYet alProtein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth
It also addresses GHKs role in increasing antioxidant enzyme activity
Side effects and storage Most reactions are mild: injection-site soreness, warmth, or redness that fades quickly, and the transient odor effect above